FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma

The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news